SLC5A2 and diabetes mellitus: However, a post hoc analysis in the CREDENCE trial demonstrated that administering SGLT2 inhibitors on top of RAAS inhibition intriguingly reduced the risk of hyperkalemia in individuals with diabetes and chronic kidney disease (28).